Amyloid-beta38 in the brains of sporadic and familial Alzheimer's disease and transgenic mouse models

Manuscript Number: 

13-1373R1

Author(s): 
Thomas A. Bayer, Melanie Huettenrauch, Martin Ingelsson, Tekla Kolbow, Lars Lannfelt, Henrik Martens, Anders Paetau, Jochim Reinert, Auli Verkkoniemi, Oliver Wirths

Disclosures

Thomas A. Bayer

  • Nothing to Disclose

Melanie Huettenrauch

  • Nothing to Disclose

Martin Ingelsson

  • Nothing to Disclose

Tekla Kolbow

  • Nothing to Disclose

Lars Lannfelt

  • Equity:
    BioArctic Neuroscience AB, small biotech company, founder and ownership of stock
    Patents/Royalties
    Patents covering BioArctic Neuroscience's Immunotherapy for Alzheimer's disease

Henrik Martens

  • Nothing to Disclose

Anders Paetau

  • Nothing to Disclose

Jochim Reinert

  • Nothing to Disclose

Auli Verkkoniemi

  • Consulting Fees:
    I am a member of Finnish advisory board of fingolimod MS-treatment which is a medication produced by Novartis. We have two meetings per year and consulting fees for those two meetings are paid.
    Lecture Fees:
    I have given lectures of MS disease, memory problems and received lecture fees from BiogenIdec, Novartis, Orion and MeckSeron

Oliver Wirths

  • Nothing to Disclose